- Home
- AYRO vs ATNF Comparison
AYRO vs ATNF Comparison
Compare AYRO & ATNF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AYRO
- ATNF
- Stock Information
- Founded
- AYRO 2017
- ATNF 2016
- Country
- AYRO United States
- ATNF United States
- Employees
- AYRO N/A
- ATNF N/A
- Industry
- AYRO Telecommunications Equipment
- ATNF Biotechnology: Pharmaceutical Preparations
- Sector
- AYRO Consumer Discretionary
- ATNF Health Care
- Exchange
- AYRO Nasdaq
- ATNF Nasdaq
- Market Cap
- AYRO 4.8M
- ATNF 4.1M
- IPO Year
- AYRO N/A
- ATNF N/A
- Fundamental
- Price
- AYRO $0.59
- ATNF $1.25
- Analyst Decision
- AYRO
- ATNF
- Analyst Count
- AYRO 0
- ATNF 0
- Target Price
- AYRO N/A
- ATNF N/A
- AVG Volume (30 Days)
- AYRO 223.6K
- ATNF 84.0K
- Earning Date
- AYRO 03-31-2025
- ATNF 03-04-2025
- Dividend Yield
- AYRO N/A
- ATNF N/A
- EPS Growth
- AYRO N/A
- ATNF N/A
- EPS
- AYRO N/A
- ATNF N/A
- Revenue
- AYRO $221,671.00
- ATNF N/A
- Revenue This Year
- AYRO $2,424.87
- ATNF N/A
- Revenue Next Year
- AYRO N/A
- ATNF $54.15
- P/E Ratio
- AYRO N/A
- ATNF N/A
- Revenue Growth
- AYRO N/A
- ATNF N/A
- 52 Week Low
- AYRO $0.49
- ATNF $1.16
- 52 Week High
- AYRO $1.83
- ATNF $17.75
- Technical
- Relative Strength Index (RSI)
- AYRO 39.78
- ATNF 33.17
- Support Level
- AYRO $0.49
- ATNF $1.31
- Resistance Level
- AYRO $0.85
- ATNF $1.38
- Average True Range (ATR)
- AYRO 0.06
- ATNF 0.06
- MACD
- AYRO -0.00
- ATNF 0.01
- Stochastic Oscillator
- AYRO 28.33
- ATNF 0.00
About AYRO AYRO Inc.
AYRO Inc design and manufacture compact, sustainable electric vehicles for closed campus mobility, low-speed urban and community transport, local on-demand and last-mile delivery, and government use. It operates as one reportable segment, which is the design, development, manufacturing, and sales of electric vehicles, and operates in the United States.
About ATNF 180 Life Sciences Corp.
180 Life Sciences Corp is a clinical-stage biotechnology company. It is focused on the development of therapeutics for unmet medical needs in chronic pain, inflammation and fibrosis by employing innovative research, and, where appropriate, combination therapy.